The trials moving the whole field forward.

Steno Copenhagen study testing whether pre-exercise low-dose glucagon prevents or blunts exercise-related glucose drops in adults with T1D using automated insulin delivery.

Phase 4/pediatric stage-2 teplizumab study, relevant after the expanding Tzield label and screening-to-treatment pathway.

Adjunct metabolic trial adding pioglitazone or placebo after a dapagliflozin lead-in in type 1 diabetes, testing whether the combination improves HbA1c without amplifying ketones.…

Tel Aviv pilot trial comparing mealtime versus post-meal dosing of ultra-rapid lispro in adults using the MiniMed 780G hybrid closed-loop system.

McGill phase 4 randomized trial testing low-dose empagliflozin added to automated insulin delivery for adults with T1D who are not meeting time-in-range targets.

Lilly randomized phase-3 trial of tirzepatide versus placebo in adults with T1D and overweight or obesity, with HbA1c change at week 40 as the primary endpoint. It is active but…

Lilly randomized phase-3 trial of tirzepatide versus placebo in adults with T1D and overweight or obesity, with HbA1c change at week 40 as the primary endpoint. It is active but…

Phase-3 trial testing whether oral baricitinib can delay progression to clinical stage-3 T1D in at-risk stage-1b/2 children and adults.

Phase-3 trial testing baricitinib in children and adults newly diagnosed with stage-3 T1D, following the positive BANDIT phase-2 result.

Sanofi's large Phase 3 confirmatory trial for teplizumab in newly diagnosed stage-3 type 1 diabetes. It is recruiting 723 participants aged 1-25 within 56 days of diagnosis and…

Vertex’s open-label stem-cell-islet study now includes VX-017 alongside zimislecel (VX-880). In the published VX-880 cohort, 10 of 12 full-dose recipients were insulin-independent…

McGill phase 3 crossover study testing semaglutide and empagliflozin, individually and combined, as adjuncts to automated insulin delivery in adults with T1D.

A second, separate Vertex phase 3 of the stem-cell-derived islet therapy zimislecel, in people with type 1 diabetes who already have a kidney transplant. They already take…

vTv Therapeutics phase 3 trial testing cadisegliatin, described by the sponsor as a liver-selective glucokinase activator, as an insulin adjunct to reduce level-2/3 hypoglycemia…

Nanjing Medical University randomized phase 3 study testing whether dimethyl fumarate capsules preserve C-peptide in adults with newly diagnosed type 1 diabetes compared with…

Novo Nordisk phase 3 trial comparing once-weekly insulin icodec with once-daily glargine U100, both with insulin aspart, in adults with type 1 diabetes.

Recruiting US/Canada Phase 3 of three years of sotagliflozin 200 mg daily versus placebo in adults with longstanding T1D and moderate-to-severe diabetic kidney disease, with an…

Swiss randomized phase 3 study testing tirzepatide as an add-on to usual care in adults with type 1 diabetes using automated insulin delivery.

A single-arm Phase 3 study in 48 adults with T1D and severe hypoglycemia despite intensive care. At one year, 87.5% reached HbA1c below 7% without severe hypoglycemic events.…

Randomized crossover study comparing 200 mg and 400 mg sotagliflozin in adults with T1D on injections or hybrid closed-loop therapy. Dual glucose/ketone monitoring measures ketone…

A landmark NIH prevention trial that screened over 100,000 relatives of people with type 1 diabetes to test whether giving insulin (by injection or by mouth) before diagnosis…

A randomized crossover study of Inreda’s insulin-and-glucagon system after total pancreatectomy. The ADA 2026 primary abstract reports 34 randomized participants and 20 who…

A phase-3 trial asking a question almost nobody else asks: can an immune therapy still protect insulin-producing cells in people who are one to two years past diagnosis, not only…

A Phase 3 trial testing whether two short courses of the immune therapy teplizumab can preserve the body's own insulin production in 8-17-year-olds newly diagnosed with type 1…

Investigator-initiated phase 3 trial (sponsor Nordsjaellands Hospital, per registry) testing weekly semaglutide titrated to 2.4 mg versus placebo for weight, insulin-dose needs,…

A large international Phase 3 trial (TrialNet) testing whether a daily oral insulin capsule could delay or prevent type 1 diabetes in autoantibody-positive relatives of people…

Phase-3 trial of Diamyd (GAD-alum) in adolescents and adults with recently diagnosed T1D who carry the HLA DR3-DQ2 haplotype, the group where prior antigen-specific immunotherapy…

Completed randomized phase-3 trial of finerenone versus placebo on top of standard care in adults with T1D and albuminuric chronic kidney disease. It met its six-month albuminuria…

Northwestern phase 3 donor-islet transplant study for non-uremic people with difficult T1D control. Now completed, with results posted in June 2026 — but of 10 people enrolled,…

DF-IL2-REP compares low-dose IL-2 (ILT-101) with placebo after a shared course of ciclosporin in recent-onset T1D. The EU registry records recruitment ending in November 2025,…

Adult phase 2 randomized trial of repeated BCG in established T1D, with juvenile-onset disease as the primary population and an exploratory LADA cohort. Active, not recruiting. An…

Ain Shams University phase 2/3 study testing autologous adipose-derived mesenchymal stem cells differentiated toward insulin-producing cells in adolescents with type 1 diabetes.

TrialNet/NIDDK phase-2 trial comparing two selective oral JAK-pathway drugs - abrocitinib and ritlecitinib - with placebo for preservation of C-peptide in newly diagnosed T1D.

A Phase 2 comparison of LY3938577 with insulin degludec in adults with type 2 diabetes previously using basal insulin. Its primary aim is noninferiority on time in range. It is…

The registry describes a phase 2 randomized placebo-controlled trial of AMX0035 (sodium phenylbutyrate plus taurursodiol), added to insulin in adults with T1D. It tests whole-body…

Adaptive phase 2 study of MTX228 in type 1 diabetes; included as a watch-list adjunct/drug-development record.

A placebo-controlled Phase 2 study of repeat BCG vaccination in children with established T1D. The registry lists active, not recruiting, with an estimated enrollment of 150; it…

A TrialNet phase 2 trial testing whether rezpegaldesleukin, an engineered IL-2 therapy described as intended to expand regulatory T cells, preserves insulin production after a…

Phase 2 study of SAB-142, a human anti-thymocyte globulin intended to permit repeat dosing. Part A assesses safety, Part B evaluates C-peptide at 12 months after two courses six…

McGill randomized placebo-controlled 2×3 factorial crossover trial of weekly semaglutide and meal strategies in adults with established T1D using advanced AID. The primary…

NIDDK TrialNet adaptive platform trial comparing teplizumab with low-dose anti-thymocyte globulin in stage-2 T1D to test whether ATG can match or beat the approved delay therapy.

A Phase 2/3 adjunct-drug study testing whether adding dapagliflozin to insulin plus semaglutide improves HbA1c. The registry lists 78 actual participants and active follow-up; no…

Active phase-2/3 trial testing ustekinumab in adults with recent-onset T1D, following earlier pilot and adolescent signals.

A newly registered phase 2/3 placebo-controlled trial testing whether oral verapamil preserves insulin secretion during the first six months after diagnosis. The registry reports…

University of Virginia phase 2 trial testing Cirius Therapeutics CIR-0602K to improve time in range and lower insulin dose in adults with T1D using closed-loop automated insulin…

Phase 2 feasibility/safety study of Diamyd antigen-specific immunotherapy in individuals at risk for type 1 diabetes.

Sanofi phase-2b trial of frexalimab, a CD40L antagonist, to preserve the body's own insulin production in children, adolescents and adults with newly diagnosed T1D. Enrolment is…

Swedish randomized phase 2 trial testing ixekizumab, an anti-IL-17A antibody used in psoriasis, for preservation of residual insulin secretion in adults with new-onset T1D.

MannKind phase 2 single-arm study of Afrezza (Technosphere insulin) plus basal insulin in children and adolescents aged 6 to under 18 with newly diagnosed stage 3 type 1 diabetes.

City of Hope phase 2 donor-islet transplant protocol using a T-cell-depleting immunosuppression induction regimen and gastrin 17.

Recruiting Chinese phase 2/3 study comparing dimethyl fumarate plus standard insulin with standard insulin alone in 96 adults with residual beta-cell function. It is nonrandomized…

Recruiting US Phase 2 of subcutaneous OPT101 per the registry. Part A is open-label dose-finding (three times weekly for two weeks); Parts B and C are 48-week placebo-controlled…

A University of Florida phase 2 trial testing low-dose ATG against placebo in newly diagnosed T1D, stratifying participants by an ex vivo immune-responder signature so that…

A TrialNet Phase 2 trial testing whether a short course of the B-cell-depleting antibody rituximab-pvvr, followed by the co-stimulation blocker abatacept, preserves the body's own…

Recruiting UK Phase 2 of 16 weeks of sotagliflozin 200 mg daily versus placebo in adults with Type 1 diabetes and heart failure or high risk of heart failure. The primary endpoint…

Randomized phase 2 study testing difluoromethylornithine (DFMO), a polyamine-pathway drug, to reduce beta-cell stress and preserve remaining insulin production in recent-onset T1D.

Sanofi phase 2 study testing the approved teplizumab delay regimen in Japanese participants aged 1–34 with stage-2 type 1 diabetes (KIBOU-T1D).

Recruiting Australian Phase 2 double-blinded placebo-controlled mechanistic clamp study of six weeks of weekly 2.5 mg tirzepatide versus saline placebo in adults with T1D on AID,…

McGill-led phase 2/3 trial testing whether weekly tirzepatide can help adults using Tandem Control-IQ reduce or eliminate carbohydrate counting and meal announcements while…

PolTREG phase 2 pediatric prevention trial testing expanded regulatory T cells, rituximab, their combination, or control in children with stage 1 type 1 diabetes. The registry…

Zucara phase 2a crossover study of ZT-01, described by the sponsor as a somatostatin-receptor antagonist intended to restore glucagon release during lows, for nocturnal…

A completed randomized phase 2 study in Egypt compared insulin injections alone with insulin plus either semaglutide or empagliflozin in adults with T1D and BMI at least 27. The…

Completed Australian phase-2 trial of weekly tirzepatide versus placebo alongside insulin in adults with T1D and obesity. Twenty-four were randomized and 22 completed 12 weeks.…

The first substudy of a new NIDDK adaptive platform trial that tries to slow type 1 diabetes before blood sugar ever goes abnormal. Participants have islet autoantibodies but…

A 26-week randomized trial in 72 adults with T1D, obesity and automated insulin delivery found that semaglutide improved a combined glucose-and-weight endpoint versus placebo.

Completed phase 2 trial of an immune therapy combined with liraglutide. It found a C-peptide preservation signal during treatment; the development program was subsequently…

A phase 2 randomized, placebo-controlled trial testing whether baricitinib — an oral JAK1/JAK2 inhibitor already used for rheumatoid arthritis — can protect the body's own insulin…

Small home-use feasibility study comparing insulin-only and insulin/dasiglucagon iLet configurations. Ten participants in the published report completed two seven-day periods,…

Phase 2 trial of icovamenib (BMF-219), an oral covalent menin inhibitor, in adults with stage-3 T1D who still had some insulin production of their own. Participants took the drug…

A crossover trial with 26 completers (ADA 2026 conference abstract) compared fully automated Lyumjev plus pramlintide without carbohydrate counting against a hybrid…

Randomized placebo-controlled trial of semaglutide in stage 1 T1D with impaired first-phase insulin secretion. It measures OGTT C-peptide over 12 months; no evidence of delayed…

Completed double-blind Phase 2b comparison of hepatocyte-directed-vesicle lispro with ordinary lispro in adults with T1D using insulin degludec, with 227 enrolled in the registry,…

Multicenter phase-2 trial of the oral tyrosine kinase inhibitor imatinib in adults within 100 days of diagnosis. It met the 12-month C-peptide endpoint, but the effect was not…

A phase 2 randomized trial of oral ladarixin in recently diagnosed T1D was stopped for futility. Results posted on 31 August 2026 do not show a C-peptide benefit over placebo.

A TrialNet Phase 2 trial testing whether a single, brief course of low-dose anti-thymocyte globulin (ATG) — with or without GCSF — can slow the immune destruction of…

Large Phase 2/3 trial that tested whether the immune drug teplizumab could protect insulin-making cells in people newly diagnosed with type 1 diabetes. It missed its main goal…

A small double-blind crossover trial in adults with T1D found that semaglutide improved glucose time in range alongside automated insulin delivery. Twenty-eight people were…

Small (estimated enrollment 10) phase 2 randomized placebo-controlled study testing whether 26 weeks of sorafenib preserves mixed-meal-stimulated C-peptide in adults with…

Phase-2 trial targeting CD2-high memory T cells with alefacept. The 12-month primary 2-hour C-peptide endpoint was not significant, but 4-hour C-peptide, insulin use, hypoglycemia…

Randomized Phase 2 trial of golimumab in 84 children and young adults with new-onset type 1 diabetes. It preserved more C-peptide and reduced insulin use at 52 weeks versus…

A landmark NIH/TrialNet trial showing that a single 14-day course of the anti-CD3 antibody teplizumab delayed the clinical onset of type 1 diabetes by roughly 2 years (median,…

A TrialNet prevention trial testing whether the inexpensive oral immune-modulating drug hydroxychloroquine could slow the earliest stage of type 1 diabetes in people with two or…

European Phase 2 trial of verapamil added to insulin in 136 newly diagnosed adults. Conference-reported results did not meet the primary intention-to-treat C-peptide endpoint. A…

A completed TrialNet Phase 2 trial testing whether 12 months of abatacept (a T-cell costimulation blocker) could delay progression from stage 1 (autoantibody-positive, normal…

vTv Therapeutics phase 2a randomized crossover study testing cadisegliatin (TTP399) versus placebo as an adjunct to insulin in adults with type 1 diabetes using hybrid closed-loop…

HealthPartners phase 2 trial developing DKA risk mitigation for people with T1D and mild-to-moderate CKD starting SGLT1/2 inhibitor therapy, using continuous glucose and ketone…

A Phase 2b trial that injected the diabetes autoantigen GAD65 (Diamyd) directly into lymph nodes to try to halt the immune attack on insulin-producing cells. It missed its overall…

AdventHealth study of a continuous-ketone-monitoring education plan for people with type 1 diabetes using sotagliflozin, including insulin-withdrawal testing to study ketone risk…

Not-yet-recruiting US Phase 2 platform matching adults with long-standing T1D and early kidney or heart-risk markers to finerenone or sotagliflozin. It is a T1D complication…

Study evaluating ketone thresholds intended to minimize ketosis risk for people with T1D using dapagliflozin.

Saudi phase 2 randomized trial testing Shingrix, semaglutide, their combination, or placebo in adults with recent-onset type 1 diabetes to assess whether immune adjuvant plus…

Terminated randomized phase-2 study of the anti-CD2 antibody siplizumab in adults with new-onset T1D. The sponsor attributed the early stop to business reasons rather than safety,…

A randomized, double-blind, placebo-controlled Phase 2 trial (TrialNet TN-09) testing whether the T-cell co-stimulation modulator abatacept could slow the loss of…

Multicenter double-blind randomized phase-2 trial of ustekinumab in adolescents with recent-onset T1D. It met its 12-month C-peptide endpoint with no increase in adverse events.

Mechanistic crossover study comparing insulin exposure and tissue glucose disposal and nitric-oxide availability. It includes T1D, GCK-MODY and control cohorts; it is not an…

Per the registry (NCT00160732), a University of Chicago phase 1/2 allogeneic islet-cell protocol using intraportal infusion plus immunosuppression, listed as active but not…

A recruiting Phase 1b/2a trial of CNP-103, a nanoparticle-based therapy designed to induce antigen-specific immune tolerance in recent-onset T1D. An ADA 2026 abstract reports…

Randomized phase 1/2 study of denosumab versus placebo in T1D diagnosed 1–5 years previously, testing adverse events and residual beta-cell function over 12 months. No results are…

Phase 1 safety study of encapsulated donor islets in Canada. July sponsor reporting describes seven participants and non-fibrotic engraftment; insulin independence has not been…

Eli Lilly's glucose-sensitive insulin candidate in healthy participants and in people with type 1 diabetes. The design is the most revealing detail: the Part D T1D arm retains…

City of Hope phase 1 study of an autologous tolerogenic dendritic-cell vaccine loaded with proinsulin peptide in adults with type 1 diabetes, focused on manufacturing feasibility…

GentiBio phase 1 study of GNTI-122, a one-time autologous engineered regulatory T-cell therapy made from the participant's own blood cells, in adults recently diagnosed with type…

Phase 1, single-arm study of autologous chemically reprogrammed islet cells in an estimated ten adults with T1D. Eligibility includes people with previous liver or kidney…

Early Phase 1/2 study of a vascularized scaffold holding donor islets under the skin, with systemic immunosuppression. The first cohort achieved insulin independence after…

UCSD crossover trial of sotagliflozin with volagidemab or placebo as insulin adjuncts in T1D. The registry lists active, not recruiting, with estimated enrollment of 24 and…

Donor-islet transplant study using tegoprubart as part of an immunosuppressive regimen that avoids calcineurin inhibitors. Eledon reported insulin independence in 12 initial…

Recruiting Japanese first-in-human Phase 1/2a of TUFF-IPC, insulin-producing cells made from a person's own fat-derived stem cells, transplanted into the mesentery. Target n=3.…

Early safety study of gene-edited donor islets transplanted without immunosuppression. Published evidence concerns one recipient, with follow-up subsequently reported to 14…

Phase 1/2 pediatric trial of verapamil for residual insulin preservation after recent-onset T1D.

A Phase 1/2 trial of Vertex's stem-cell-derived islets sealed inside an immune-protective device, aiming to restore insulin production without lifelong immunosuppression. In March…

Very early (registry "Early Phase 1") single-site study at Zhongshan Hospital, Shanghai, of an off-the-shelf CD7-targeted CAR-T cell product (RD13-02) in 9 adults with stage 2 or…

Recruiting Australian Phase 1, randomised, double-blind, placebo-controlled study of subcutaneous proinsulin peptide/calcitriol liposomes (ASITI-201) in adults with stage 3 T1D.…

Nanjing Drum Tower Hospital recruiting phase 1 study (registry NCT06708780, estimated enrollment 20) of ex vivo expanded autologous regulatory T cells plus routine care in people…

A randomized Phase 1/2a trial testing whether a single intra-arterial infusion of CELZ-201 perinatal tissue-derived cells is safe and potentially beneficial in adults within 180…

EndoCell Therapeutics' Phase 1/2a trial of allogeneic human E-islet 01 in adults with long-standing T1D, impaired hypoglycemia awareness, and severe hypoglycemia. The cells are…

Phase 1/2 trial testing whether gastrin can improve donor-islet transplant outcomes in type 1 diabetes.

Vanderbilt pilot crossover study of single-dose oral semaglutide (Rybelsus) versus placebo during MMTTs, mainly in stage 2 T1D around clinical teplizumab treatment, with a…

A two-person safety study putting donor islets into the front chamber of a blind eye — a site chosen because the graft can be watched through a microscope, and because the eye may…

City of Hope protocol testing islet transplantation alone in difficult-to-control T1D using a glucocorticoid-free immunosuppressive regimen.

Recruiting Dutch Phase 1b of autologous tolerogenic dendritic-cell therapy in adults with T1D diagnosed within five years. Target n=10. Safety and immune effect are the questions.…

Novo Nordisk Phase 1 crossover in adults with established T1D, testing weekly NNC0194-0499 (zalfermin, an FGF21 analogue) versus placebo, alone or on top of weekly semaglutide,…

First-in-human Otsuka study of OPF-310, encapsulated neonatal porcine islet cells for xenotransplantation, in adults with unstable T1D and repeated severe hypoglycemia despite…

Recruiting US Phase 1 single-bolus 12-hour euglycemic clamp of Portal Diabetes’ investigational intraperitoneal U-500 insulin (PI-U500) in adults with Type 1 diabetes, compared…

Recruiting German Phase 1 euglycemic-clamp crossover of Sam Chun Dang’s oral regular human insulin (SCD0503, S-PASS platform) versus subcutaneous regular human insulin in men with…

WAVE T1D tests a sequence rather than a single drug: a short induction course of low-dose anti-thymocyte globulin to quiet the immune attack, then either adalimumab (an anti-TNF…

A completed 41-person study of oral DFMO, a polyamine-synthesis inhibitor. It met its safety and tolerability endpoint and generated an exploratory C-peptide signal for later…

Open-label pilot of intralymphatic GAD-alum plus vitamin D in 12 people with recent-onset T1D. It reported tolerability, immune responses and apparent C-peptide preservation, but…

Altheia first-in-human trial using a person's own CD34+ hematopoietic stem and progenitor cells, genetically modified ex vivo to express PD-L1, for recent-onset T1D with residual…

Lilly’s first-in-human LY3938577 study enrolled 66 healthy adults or adults with type 2 diabetes. It completed in June 2024, with no results posted. It contains no T1D…

Novo Nordisk's glucose-sensitive insulin (GSI) candidate, tested in healthy participants and in people with type 1 diabetes. Three parts: single ascending dose, a…

A second, smaller Novo Nordisk Phase 1 of the same glucose-sensitive insulin, run only in people with type 1 diabetes and built around a glucose clamp. The primary endpoint — area…

A completed Novo Nordisk phase 1 crossover study comparing investigational insulin NNC0471-0119 H against insulin aspart, each given as a pump bolus. Per the registry, it measures…

A completed, placebo-controlled Phase 1b study of the CD154-derived peptide OPT101 in 24 adults with T1D. Results posted 10 August 2026 show a small safety dataset and no…

SC451 is a planned stem-cell-derived hypoimmune islet therapy, intended to restore insulin production without immunosuppression. Sana’s August 2026 update and September investor…

A Lilly-sponsored phase 1 randomized placebo-controlled single-dose study (first posted 4 September 2026) of how tirzepatide affects stomach emptying in adults with T1D and…

Early trial of stem-cell-derived pancreatic progenitors inside an immune-protective implant, without anti-rejection drugs. The study enrolled 19 people and was terminated for…

A first-in-human Phase 1 study of gene-edited, stem-cell-derived pancreatic cells in an implanted device, intended to function without immunosuppression. The seven-participant…

Phase 1 study of gene-edited pancreatic cells in a removable implant. The terminated study enrolled five participants. An August 2026 company presentation reports 12-month…

City of Hope pilot study testing whether autologous anti-CD6 chimeric antigen receptor regulatory T cells can be manufactured and safely infused in adults with stage-3 type 1…

Registry-described early-Phase 1 open-label dose-escalation study of a single dose of CARC-101C in autoimmune type 1 diabetes (registry-estimated enrollment 12; not yet…

Exploratory early-phase study of allogeneic iPSC-derived pancreatic islet cells given by portal-vein infusion or anterior rectus sheath transplantation in type 1 or pancreatogenic…

Terminated Phase 1/2 anti-CD2 antibody study in recent-onset T1D. Enrollment was held after greater-than-anticipated lymphocyte depletion; the partner then stopped development of…

A planned first-in-human Phase 1 study of ENC-103, Encellin's follow-on encapsulation device - a soft, roughly quarter-sized pouch loaded with donor human islets and implanted in…

Immunocore Phase 1/1b single- and multiple-ascending-dose study of IMC-S118AI, a pre-proinsulin × PD-1 ImmTAAI molecule, in HLA-A*02:01-positive people with Type 1 diabetes who…

Trial testing donor-islet transplantation combined with recipient regulatory T cells or deceased-donor vertebral bone marrow therapy to improve immune tolerance. As of July 2026…

Sequential combination protocol for recent-onset T1D: teplizumab induction, intralymphatic insulin immunotherapy, and low-dose IL-2 maintenance to combine immune quieting with…

First-in-human Seraxis phase 1/2 study of allogeneic pancreatic endocrine cell clusters implanted into the omentum of adults with type 1 diabetes and severe recurrent…

StenoAD1 compares hydrocolloid and silicone-based patches underneath diabetes devices in children and adolescents with device-related contact dermatitis. Recurrence of dermatitis…

AB-CDE randomizes adults with T1D using multiple daily injections to DailyDose decision support with additional education when indicated, or usual care with the app in…

MiniMed pivotal safety study of the system now publicly launched as MiniMed Flex and still registered under the NMX8-AID name, paired with the DS5 / Simplera Sync sensor.…

A single-arm study evaluates DreaMed’s MODI insulin-dose guidance in adults with type 1 or type 2 diabetes. Its primary safety question concerns time spent below 54 mg/dL (3.0…

PREDIDIA compares a combined three-autoantibody test on capillary blood collected on blotting paper with individual venous-blood assays in children presenting with stage 3 T1D.…

A randomized study compares Accu-Chek SmartGuide with its Predict app against fingerstick glucose monitoring in adults with type 1 or insulin-treated type 2 diabetes. The planned…

A recruiting German before-and-after study plans to enroll 89 adults with T1D or insulin-treated T2D. Participants use SmartGuide without Predict for two weeks, then with Predict…

A Texas A&M basic-science study of insulin measurement in sweat and interstitial fluid. The registry targets 92 participants and lists recruiting in its August 2026 update, but an…

Trial comparing automated insulin delivery with usual insulin treatment before and during pregnancy in women with type 1 diabetes.

Randomized study of switching to automated insulin delivery versus usual care in adults and children with T1D. The primary outcome is sleep efficiency measured over three nights…

Single-group allogeneic regenerative-islet transplantation protocol in T1D with recurrent severe hypoglycemia despite intensive insulin treatment. It measures glucose control and…

A free US research screening program for children aged 1–17 and adults, with or without a family history of T1D or celiac disease. Colorado appointments, mailed Labcorp collection…

Bavarian population screening for islet autoantibodies showed that screening young children in primary care is feasible. The observational cohort had a low frequency of DKA among…

Yale observational study validating a self-administered fingerstick glucose tolerance test against in-clinic venous OGTT measurements in people at risk for clinical type 1…

Four-arm randomized trial in adults with T1D on multiple daily injections (MDI), comparing BetaBionics iLet, Insulet OP 5 (Omnipod 5), Tandem Control-IQ or continued MDI, all with…

OHSU single-arm study of a fully closed-loop iPancreas algorithm that detects hyperglycemia patterns and delivers correction insulin, comparing glucose control during 3 weeks with…

An investigational glucose-sensing accuracy study in insulin-treated adults with type 1 or type 2 diabetes. It is a mixed-population measurement study, not evidence that the patch…

Clinical evaluation of Medtronic implantable insulin pump technology in adults with T1D, a rare long-horizon delivery-device pathway.

Study of MiniMed 780G performance in people with T1D complicated by gastroparesis, a difficult meal-absorption context for AID.

Recruiting European/Israeli study comparing Medtronic's experimental NMX8 AID system with the MiniMed 780G over 12 weeks in people aged 2 and older with insulin-requiring diabetes.

Automated-insulin-delivery trial comparing qualitative meal-size estimation against formal carbohydrate counting.

A sequential stem-cell and islet-transplant study for rare monogenic immune disorders accompanied by insulin-dependent diabetes. Its highly selected population is not…

Trial comparing simplified meal boluses with carbohydrate counting in adolescents using hybrid closed-loop systems.

Insulet randomized crossover trial comparing investigational Omnipod 6 with Omnipod 5 in people with type 1 or type 2 diabetes and suboptimal glycemia. It is the confirmatory…

A Danish crossover study in children and adolescents using MiniMed 780G, comparing three-day and seven-day infusion-set wear. Its primary outcome is ultrasound-detected tissue…

The backbone US/international screening and natural-history study that tests blood from relatives of people with T1D for islet autoantibodies, then monitors those who test…

Active, not recruiting one-visit autoantibody screen in underserved children and adults in eight Florida counties who have a relative with T1D, another autoimmune disease, or…

Randomized crossover study in which an algorithm reviews CGM and pump data and proposes personalized setting changes; physicians must approve every recommendation before it…

UVA randomized at-home trial of AIDANET, comparing fully closed-loop, hybrid closed-loop, and mixed-mode operation in adults with T1D.

UCSF multicenter randomized trial testing whether automated insulin delivery can replace intravenous insulin protocols for intrapartum glucose management in pregnant people with…

Sanofi's recruiting observational cohort following people who received teplizumab for stage 2 T1D as part of ordinary care, for up to 10 years. It measures time to stage 3 and…

Recruiting UK study comparing finger-prick glucose with venous OGTT and testing whether a capillary OGTT can be performed acceptably at home. Its T1D cohorts include young people…

Study evaluating the accuracy and precision of the CareSens Air 3 continuous glucose monitoring system in adults with T1D.

Recruiting Chinese investigator-initiated first-in-human study of CNK-UT009, a universal CAR-T / NKT cell product, in adults with autoimmune Type 1 diabetes who still have…

Observational pregnancy study comparing commercial and open-source closed-loop use in pregnant people with T1D, with registry-listed maternal, neonatal, glycemic, and…

Recruiting Sanofi-sponsored study screening an estimated 3,500 children and adolescents who have a first-degree relative with T1D at sites in Kuwait, Saudi Arabia and the UAE,…

An observational study of Medtronic's InPen connected insulin pen in adolescents and young adults with T1D per the registry. No results posted; primary completion is estimated…

Senseonics multicenter study evaluating the performance and safety of the Eversense Gemini system with flash glucose measurement enhancements against reference glucose and the…

Post-approval study of non-adjunctive Eversense CGM use, relevant to long-wear implantable CGM maturity.

University of Colorado/UVA feasibility testing of AIDANET fully closed-loop operation at home in adolescents and adults, including groups with higher baseline HbA1c.

Beta Bionics prospective real-world cohort collecting one-year safety and effectiveness data for the iLet Dosing Decision Software in people aged 6 and older with type 1 diabetes.

Randomized crossover study asking whether inhaled Technosphere insulin for a meal is safer than a pump-delivered rapid-acting analogue when adults using Control-IQ exercise soon…

Recruiting European observational screening protocol testing islet autoantibodies in children and adults aged 1–45 who have a relative or close friend diagnosed with T1D before…

University of Chicago recruiting protocol for allogeneic human islet transplantation in brittle T1D.

Safety/effectiveness study of the Luna automated insulin-delivery system in people with T1D.

Recruiting New Zealand study evaluating investigational Omnipod M and Omnipod S automated-insulin-delivery systems in people aged 2-70 with T1D.

Recruiting Belgian study using repeated Dexcom CGM, oral glucose-tolerance tests, and (in older participants) hyperglycemic clamps to see whether glucose-variability patterns can…

Non-interventional extension following participants who completed teplizumab PROTECT to collect longer-term safety and other clinical data over 42 months, per registry.

Novo Nordisk observational study following adults with type 1 diabetes newly prescribed once-weekly insulin icodec in usual clinical practice in Germany and Italy.

Czech real-world study evaluating efficacy and safety of the Medtrum TouchCare Nano A8 patch pump with APGO automated insulin-delivery algorithm.

Study of the ROME GS glucose sensing system in people with diabetes, included as CGM pipeline surveillance.

Long-term Sanofi registry following people with stage 2 type 1 diabetes, including those treated with Tzield (teplizumab-mzwv) as standard care, to collect safety, pregnancy, and…

Newly registered 15-day study comparing the GS3 real-time CGM with venous plasma reference measurements across glucose ranges in 36 adults with T1D.

Recruiting Sanofi chart-review study of people who already received teplizumab for stage 2 T1D through managed-access programmes. It describes who was treated and how they were…

A small Iranian study reported two BCG doses versus saline in children with established T1D. Its 18-month HbA1c finding is a within-BCG-group comparison, with no corresponding…

A completed US observational study followed children aged 2 to under 6 prescribed Control-IQ version 1.5. The primary endpoints are severe hypoglycemia and ketoacidosis rates; no…

A completed randomized US pilot enrolled 11 participants aged 12–22. It compared Control-IQ using Lyumjev with experimental settings against Humalog or Novolog with optimized…

A Strasbourg observational study targeting 25 adults with T1D on an islet-transplant waiting list. It explores whether extracellular vesicles from islet preparations relate to…

PROMISE-GX plans to study glucose metrics and user experience with MicroTech’s GX-01S sensor and LinX app in adults with T1D or T2D. The registry still says not yet recruiting…

A completed Greek randomized crossover study enrolled 20 adults with T1D to compare three supervised high-fat-meal strategies. Despite a title naming 640G and 780G, the protocol…

A planned 200-person Belgian observational cohort of pediatric Omnipod 5 adoption and routine-care outcomes. No results are posted. The registry contains conflicting age limits…

A UK randomized crossover study testing whether Control-IQ changes neuropathic pain in adults with established T1D. The protocol targets 40 randomized participants; no outcome…

A historical randomized trial in 143 children compared Dexcom G5 CGM with or without family behavioral support against fingerstick monitoring. The primary time-in-range comparison…

European randomized trial in adults with T1D and HbA1c at least 8% using injections plus flash CGM. MiniMed 780G lowered HbA1c by an adjusted 1.42 percentage points more than…

Study of artificial-intelligence bolus priming layered onto an existing fully automated AIDANET algorithm.

UK randomized trial in 124 pregnant women with T1D. CamAPS FX improved pregnancy-specific time in range by an adjusted 10.5 percentage points versus standard insulin therapy. It…

Single-group feasibility study collecting paired Argus 2.0, venous-reference and Dexcom Stelo measurements during a clinic visit and 15 days of home wear. It includes T1D, T2D and…

A randomized trial in 73 adults compared an open-source AID system without meal announcement against the same system with meal announcement after a 12-week run-in. Final time in…

A randomized trial of a specific open-source AID configuration: OpenAPS in modified AndroidAPS with a preproduction DANA-i pump and Dexcom G6. In 97 children and adults with T1D,…

A UK general-population screening study for early type 1 diabetes. The current ELSA program covers ages 2–17 but its official website says screening is paused. Earlier results in…

Feasibility study of extended-wear insulin infusion set options during home use in T1D.

The first head-to-head crossover trial of two automated insulin delivery systems in adolescents and young adults (eligible ages 14 to under 30). The advanced hybrid closed-loop…

A planned observational recall study asking whether genetic risk can help identify adults with early T1D. It compares the top 2.5% of a T1D polygenic score with the remainder of…

The main 13-week randomized comparison included 326 adults and children with T1D: 219 using iLet with aspart/lispro and 107 using standard care. HbA1c improved and CGM time below…

A 243-person, 12-month randomized Dutch trial (DARE, NCT05669547) testing the Inreda AP — a fully automated, dual-hormone (insulin + glucagon) artificial pancreas that runs…

Registered single-arm study of infused iPSC-derived islet cells in an estimated 30 adults with longstanding insulin-treated diabetes. The registry lists phase N/A and not yet…

Oregon Health & Science University ran the same model-predictive-control closed loop two ways — insulin only, and insulin plus the amylin analogue pramlintide — in 33 adults with…

The pivotal single-arm trial of the Omnipod 5 tubeless, on-body hybrid closed-loop system in children and adults with type 1 diabetes. It showed improved HbA1c and time-in-range…

Single-arm multicenter trial that tested the tubeless Omnipod 5 automated insulin delivery system in 80 very young children (ages 2.0-5.9) with type 1 diabetes. Over 13 weeks it…

Registry/observational study of open-source artificial-pancreas system use among people with T1D in China.

Insulet's pivotal crossover trial of SmartAdjust 2.0 — the algorithm behind the next Omnipod. 132 existing Omnipod 5 users, aged 2 to 70, spent four weeks on each system. Then…

A newly registered single-arm study of the twiist pump and Tidepool Loop algorithm in pregnancy with pre-existing T1D. It plans 32 participants and is not yet recruiting.

Newly registered observational study of Abbott's investigational continuous dual glucose/ketone monitor in 1,200 adults and children with T1D. The study arm describes three months…

First registered study of Indigo's HALO implantable sensor, evaluating glucose, ketone and lactate accuracy and stability against venous reference measurements, plus implantation…

A randomized crossover trial in 74 children aged 1-7 with type 1 diabetes found that the CamAPS FX hybrid closed-loop system (an "artificial pancreas") increased time-in-range by…